6th September 2010. Bridgehead International Ltd announced today that it has entered into an agreement with RXB Management Consulting, of Shanghai, China to provide certain joint services to clients in the pharmaceutical, medical device and diagnostics sectors.
As a major growth market, China should be considered as a key component of any international company's future strategy. Bridgehead and RXB have brought together a highly experienced team to provide a comprehensive resource to support clients in their China market access strategy, covering:
In addition, the team is able to assist clients in all aspects of market analysis, market entry and partnering.
Timothy Fitzgerald, CEO of Bridgehead International said, "We are delighted to confirm RXB Management Consulting as our partner in China. For many of our major pharmaceutical clients, China is already a key focus point from a pricing, market access and health policy perspective. In order to meet the needs of such clients, and those who are seeking help to understand the opportunities in this exciting new market, having the right partners on the ground is essential."
Betty Su, Partner & Managing Director of RXB Management Consulting said, "RXB was set up to facilitate Sino-Foreign business transaction and knowledge transfer in the health care sector. I'm convinced that the collaboration between the two companies - RXB and Bridgehead - will benefit our common clients in terms of developing a solid understanding of the exciting and yet complex Chinese health care market."
To learn more about Bridgehead's services in China, contact Timothy Fitzgerald, CEO, on +44 1664 503 700 or via email to timothy.fitzgerald@bridgehead.com
Bridgehead International (www.bridgehead.com) is a leading biopharmaceutical consultancy group, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain. Our mission is to work with commercial organisations, government agencies and the investment community to ensure that:
With over 40 consultants and 60 associates in Europe, North America and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience. Bridgehead is globally recognised for its expertise in:
In 2007, Bridgehead was honoured with The Queen's Award for Enterprise, in the International Trade section, for outstanding achievement in international trade. The Queen's Award for Enterprise is the highest honour that can be bestowed upon a UK company and is the UK's top award for business performance.
In 2009, Bridgehead was voted UK Strategic Advisor of the Year - Healthcare, in the ACQ Finance Magazine's Global Awards.
RXB Management Consulting (Health Care) was established in 2009 by Mr Steen Kroyer (Chairman) and Ms Betty Su (Managing Director). RXB specialises in pharmaceutical and medical device market analysis, market entry and partnering strategy and solutions for the Chinese market.
Mr Kroyer was previously President and Chairman of AstraZeneca China, where he was responsible for developing AstraZeneca into one of the leading pharma companies in China with sales of more than USD 800 million this year. His responsibilities included commercial operations in China and Hong Kong, manufacturing in Wuxi, R&D investment strategy and industry and government relations.
Ms Su was previously Brand Manager, AstraZeneca China, where her major responsibilities included product portfolio management, marketing strategy and planning, campaign execution, internal and external stakeholder management. Prior to that she was Corporate Affairs Manager, AstraZeneca, China, responsible for external stakeholder management, relationship maintenance and internal communication. She was also Chair of the Labour Union.
The company has a core team of consultants and a network of collaborators with extensive industry and professional experience.
